Summary

In some cases of non—small cell lung cancer (NSCLC), mutations in oncogenes appear to be the underlying mechanism of lung cancer development. Specifically targeted therapies are promising in the treatment of NSCLC, but mutations in oncogenic drivers can result in drug resistance. This article discusses drug resistance to ALK and ROS1 inhibitors, as well as BRAF and HER2 mutations that result in drug resistance.